Regeneron Pharmaceuticals (REGN) Profit Margin History

Historical gross, operating and net quarterly profit margin for Regeneron Pharmaceuticals (REGN) over the last 10 years. The current net profit margin for Regeneron Pharmaceuticals as of March 19, 2018 is 20.41%.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $36.518B $5.872B
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.